Evidence map›Paper›PMID 38183096›Full record

ArticlePediatric rheumatology online journal2024

Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe.

Alexei A Grom, Scott W Canna, Rolla F Abu-Arja, Rashmi Sinha, Luciana Peixoto, Elvira Cannizzaro, Shanmuganathan Chandrakasan, Kyla Driest, Rebecca Marsh, Bénédicte Neven and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric rheumatology online journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 5 countries.

Alexei A GromDivision of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA. Alexi.Grom@cchmc.org.
Scott W Canna *Rheumatology & Immune Dysregulation, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Rolla F Abu-Arja *Department of BMT, Nationwide Children's Hospital, Columbus, OH, USA.
Rashmi Sinha *Systemic JIA Foundation, Cincinnati, OH, USA.
Luciana Peixoto *Systemic JIA Foundation, Cincinnati, OH, USA.
Elvira Cannizzaro *Department of Rheumatology, University Children's Hospital, Zurich, Switzerland.
Shanmuganathan ChandrakasanDepartment of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA.
Kyla DriestDepartment of Rheumatology, Nationwide Children's Hospital, Columbus, OH, USA.
Rebecca MarshDivision of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Bénédicte NevenPediatric Hematology-Immunology and Rheumatology Department, Necker-Enfants- Malades University Hospital, Paris, France.
Karen OnelDepartment of Rheumatology, HSS, New York City, NY, USA.
Sampath PrahaladDepartment of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA.
Susan ProckopDana Farber/Boston Childrens Hospital Center for Cancer and Blood Disorders, Boston, MA, USA.
Pierre QuartierPediatric Hematology-Immunology and Rheumatology Department, Necker-Enfants- Malades University Hospital, Paris, France.
Johannes RothKantonsspital Luzern, University of Luzern, Luzern, Switzerland.
Grant SchulertDivision of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.
Juliana M F SilvaDepartment of BMT, Great Ormond Street Hospital for Children, London, UK.
Donna Wall16. Blood and Marrow Transplant/Cellular Therapy, Division of Haematology/Oncology, Hospital for Sick Children Toronto, Toronto, Canada.
Ulrike ZeilhoferDepartment of BMT, University Children's Hospital, Zurich, Switzerland.
Cincinnati Children's Hospital Medical Center · USNationwide Children's Hospital · USUniversité Paris Cité · FRUniversity Children's Hospital Zurich · CHChildren's Healthcare of Atlanta · USChildren's Hospital of Philadelphia · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · USEmory University · USHospital for Sick Children · CALuzerner Kantonsspital · CHUniversity College London · GBUniversity of Cincinnati · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been increasingly recognized that there is a subset of patients with refractory systemic JIA, who have failed all available medications and may benefit from HSCT. The increasing experience with HSCT in SJIA, suggests that despite the complicated post-HSCT course, short-term, the transplanted patients either achieved SJIA remission or reduced burden of disease. Longer follow-up, however, is needed to better define the long-term outcomes. The discussion at the NextGen 2022 conference was focused on the optimal timing for the procedure, the need for a good control of inflammatory SJIA activity prior to HSCT, and the role of the reduced intensity conditioning regimens as there was a remote concern that such regimens might increase the risk of SJIA relapse after the transplantation. There was unanimous agreement about the importance of long-term registries to address these questions.

Indexed as

Hematopoietic Stem Cell TransplantationLung DiseasesEuropeHumansNorth AmericaRegistriesAllogeneic HSCTHLA DRB1*15 allelesMASRefractory SJIASJIA-LD

Identifiers

PMID38183096
PMCPMC10768073
OpenAlexW4390615638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.